In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PlanetRx: Drugs & Perfume.com

Executive Summary

Although only six-months old, the cyber drugstore industry has generated considerable publicity and made a big impression on investors. Three major players--PlanetRx.com., drugstore.com & Soma.com-- have emerged thus far, and are engaged in a furious battle to quickly gain market share. The first major hurdle that these companies must clear is signing on third party payers, many of which own or have exclusive relationships with mail order prescription services. But the biggest challenge facing PlanetRx and its competitors is to establish themselves as partners in Web-based networks which link them with providers, third party payers and other health care influencers.

You may also be interested in...



Coronavirus Update: Japan's Supercomputer Joins COVID-19 Drug Hunt

Developed by Japan’s national research institute, the supercomputer has been tasked with characterizing the SARS-CoV-2 virus, identifying therapeutic molecules, modeling infection spread and socio-economic impact.

Pipeline Watch: First Approvals For Vadadustat, Daprodustat, In Japan

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

MiMedx Raises $150M To Scale Advanced Wound Care Product Biz

Wound care company MiMedx has raised $150m in private equity and debt financing from EW Healthcare Partners and Hayfin Capital Management. The funds will be used to scale commercialization of the company’s amniotic tissue products.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel